2019 Silicon Valley Bank Annual Report Jan 1, 2019
Silicon Valley Bankの年次レポート（2019年版）において、バイオファーマ業界におけるVCの資金調達動向、ベンチャーのエグジット動向、2019年の見通しが纏められています。
2018 Highlights: Investments
- US healthcare venture fundraising reached a record $9.6B, continuing a four-year upward trend
- Venture investments increased 50 percent over 2017, setting a record.
- Biopharma dollar volume doubled that of 2017
- Biopharma Series A dollars increased 35 percent, led by oncology and platform companies, which accounted for more than half of all deals and dollars
- With nearly twice the number of 2017 deals, Top 15 Crossover Investors restocked biopharma IPO pipelines by funding 60 private companies
2018 Highlights: Exits
- 2018 was a banner year for biopharma IPO and M&A exits, hitting a record total deal value of $49B
- Biopharma IPOs reached a five-year high in pre-money valuations and dollars raised, and private M&A posted a 5x median
- Upfront multiple and a median time to exit of just over three years
- A record 18 $1B+ venture-backed biopharma IPOs and M&A deals were completed in 2018
2019 Outlook
- We anticipate total US investment into life science to continue at a healthy pace, reaching about $8B, with established funds likely to be joined by new spinout funds anchored by established investors. In addition, tech firms may raise life science–only sister funds
- Top 15 Crossover investment in venture-backed companies could soften by 25 percent or more, leading to biopharma investments decreasing to more closely match 2017 numbers
- The biotech IPO pipeline is strong, but market uncertainty could drag IPOs down to 30 to 35 deals and moderately reduce pre-money valuations and dollars raised. As a result, we expect an increase in private biopharma M&As
You can find more information at the following link:
詳細については下記のリンクを参照してください。
Trends in Healthcare Investments and Exits 2019, SVB